← Leaderboards
Sachin Bhagchandani
Massachusetts Institute Of Technology
$400,483
Attributed
$400,483
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $109.1K · FY2021–25$200K$150K$100K$50K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$400,483 · 2
By mechanism
K00$307,695 · 1
F99$92,788 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts Institute Of Technology
Same institution · by research overlap
- Paula T Hammond$10,864,288
- Karl D Wittrup$33,463,127
- Bruce R Rosen$77,364,146
- Daniel G Anderson$11,913,058
- Tyler E Jacks$53,083,831
Others in their field
Other Emerging Leaders on “Agonist”
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
- Aaron Esser-Kahn · University Of Chicago$13,378,548
- Nikej Shah · Nirsum Laboratories, Inc.$12,506,430
- Xinhua Li · Nano Terra, Inc.$11,941,250
- James Dale Berry · Brigham And Women'S Hospital$9,298,517
- James N Campbell · Centrexion Therapeutics Corporation$8,662,635
Research focus
AgonistAnti-Ctla4Anti-Pd1 AntibodiesAnti-Tumor Immune ResponseAppropriate DoseArchitectureAutoimmunityBiodistributionBloodCancer CellCancer ImmunotherapyCancer PatientCancer TherapyCellsChemistryClinicClinical PracticeClinical TrialsCombination ImmunotherapyCreamCytotoxic T-LymphocytesDendritic CellsDesignDisease Model
Grant awards (5)
Toward safe, systemic immunotherapies for treatment of metastatic disease: Developing dendritic cell-biased immunomodulators with precise control over magnitude and timing of immune stimulation$109,061
K00 · FY2025 · CA · contact PI
Toward safe, systemic immunotherapies for treatment of metastatic disease: Developing dendritic cell-biased immunomodulators with precise control over magnitude and timing of immune stimulation$104,840
K00 · FY2024 · CA · contact PI
Toward safe, systemic immunotherapies for treatment of metastatic disease: Developing dendritic cell-biased immunomodulators with precise control over magnitude and timing of immune stimulation$93,794
K00 · FY2023 · CA · contact PI
Toward safe, systemic immunotherapies for treatment of metastatic disease: Developing dendritic cell-biased immunomodulators with precise control over magnitude and timing of immune stimulation$46,752
F99 · FY2022 · CA · contact PI
Toward safe, systemic immunotherapies for treatment of metastatic disease: Developing dendritic cell-biased immunomodulators with precise control over magnitude and timing of immune stimulation$46,036
F99 · FY2021 · CA · contact PI